Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
54.87
+2.93 (5.64%)
At close: Jun 25, 2026, 4:00 PM EDT
54.25
-0.62 (-1.13%)
Pre-market: Jun 26, 2026, 8:46 AM EDT
Tempus AI Revenue
Tempus AI had revenue of $348.12M in the quarter ending March 31, 2026, with 36.12% growth. This brings the company's revenue in the last twelve months to $1.36B, up 69.82% year-over-year. In the year 2025, Tempus AI had annual revenue of $1.27B with 83.41% growth.
Revenue (ttm)
$1.36B
Revenue Growth
+69.82%
P/S Ratio
7.22
Revenue / Employee
$358,992
Employees
3,800
Market Cap
9.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 578.39M | 83.41% |
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 13.65B |
| Veeva Systems | 3.32B |
| Teladoc Health | 2.51B |
| Privia Health Group | 2.25B |
| HealthEquity | 1.34B |
| Omnicell | 1.23B |
| Waystar Holding | 1.16B |
| Hinge Health | 646.34M |
TEM News
- 1 day ago - Tempus AI announces research collaboration with Angiosarcoma Awareness - TheFly
- 1 day ago - Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers - Business Wire
- 9 days ago - Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms - FXEmpire
- 15 days ago - Tempus AI announces publication of multi-center validation of software - TheFly
- 15 days ago - Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm - Business Wire
- 17 days ago - Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing - Business Wire
- 17 days ago - Tempus AI Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire